Hackensack University Medical Center Becomes Global Med Technologies, Inc. Vein-to-Vein(R) Client
May 14 2007 - 10:00AM
PR Newswire (US)
Purchase Decision Follows One Year Extensive Competitive Evaluation
Process DENVER, May 14 /PRNewswire-FirstCall/ -- Wyndgate
Technologies(R), a division of Global Med Technologies(R), Inc.
(OTC:GLOB) (BULLETIN BOARD: GLOB) , today announced that Hackensack
University Medical Center (HUMC), one of the nation's premier
university-based teaching hospitals, has purchased both
SafeTrace(R) software to manage its donor center and SafeTrace
Tx(R) software to manage its transfusion service, making it
Wyndgate's newest Vein-to-Vein(R) client. Terms of the agreement
were not disclosed. (Logo:
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO )
Hackensack University Medical Center, with a budget of over $1
billion, is affiliated with The University of Medicine and
Dentistry of New Jersey-New Jersey Medical School. HUMC is the
largest provider of inpatient and outpatient services in the state
of New Jersey and the fourth largest provider of inpatient services
in the nation based on admissions. Kathleen A. Reilly, MT(ASCP)SM,
Administrative Director, Pathology at HUMC, stated, "We believe
that selecting an information system is a major decision and, as
such, we have been very thorough in our selection process. We
evaluated Wyndgate Technologies for over a year and during that
time we have gotten to know the company's people and the company's
products. We have found Wyndgate to be responsive and informative.
They are attentive and customer-focused. Wyndgate's SafeTrace and
SafeTrace Tx* software systems are well-designed and we believe
they will meet the diverse needs of our large operation. We look
forward to working with the company and implementing our new
systems." Thomas F. Marcinek, President of Wyndgate Technologies,
commented, "Hackensack University Medical Center is a vital nucleus
for healthcare in northern New Jersey and the New York metropolitan
area. HUMC recognizes this essential role and its need for a system
that can meet its current needs and help it continue to keep
abreast of changing regulations." Mr. Marcinek continued, "HUMC
examined the entire market and took a considerable amount of time
to evaluate its leading choices. In light of this thoroughness,
Wyndgate is particularly proud to have been selected by HUMC, which
demonstrates their confidence in SafeTrace and SafeTrace Tx." About
Hackensack University Medical Center HealthGrades recently named
Hackensack University Medical Center as one of America's 50 Best
Hospitals for 2007. This designation, which is new this year,
recognizes hospitals that have demonstrated superior clinical
quality over a seven-year time period, based upon an analysis of
more than 75 million Medicare patient records from 1999-2005. These
hospitals have achieved better survival rates and lower
complication rates across dozens of medical procedures and
diagnoses, from cardiac care to orthopedic surgery, consistently
ranking among the top five percent in the nation for overall
clinical outcomes. Hackensack University Medical Center is the only
healthcare facility in New Jersey, New York, and New England to be
named one of America's 50 Best Hospitals. About Global Med
Technologies, Inc. Global Med Technologies, Inc. is an
international e-Health medical information technology company
providing information management software products and services to
the healthcare industry. Its Wyndgate Technologies division is a
leading supplier of information management systems to U.S. and
international blood centers and hospital transfusion centers. Each
year, Wyndgate's products and services manage more than eight
million blood components, representing over 27% of the U.S. blood
supply. Wyndgate's products are being used in Canada and
sub-Saharan Africa, and are being implemented in the Caribbean.
Together, the SafeTrace Tx(R) advanced transfusion management
system and the SafeTrace(R) donor management system provide
Vein-to-Vein(R) tracking from donor collection to patient
transfusion. For more information about Global Med's products and
services, please call 800-WYNDGATE or visit
http://www.globalmedtech.com/, http://www.peoplemed.com/ and
http://www.wyndgate.com/. This news release may include statements
that constitute forward-looking statements, usually containing the
words "believe," "estimate," "project," "expects" or similar
expressions. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this news release.
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO
http://photoarchive.ap.org/ DATASOURCE: Global Med Technologies,
Inc. CONTACT: Michael I. Ruxin, M.D. of Global Med Technologies,
Inc., +1-303-238-2000; or Investors, Paul Holm, +1-212-888-4570,
for Global Med Technologies, Inc. Web site:
http://www.peoplemed.com/ Web site: http://www.wyndgate.com/ Web
site: http://www.globalmedtech.com/
Copyright